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Abstract: Acetazolamide (ACZ) was used to stimulate the cerebral
vasculature on ten healthy volunteers to assess the cerebral vasomotor
reactivity (CVR). We have combined near infrared spectroscopy (NIRS),
diffuse correlation spectroscopy (DCS) and transcranial Doppler (TCD)
technologies to non-invasively assess CVR in real-time by measuring
oxy- and deoxy-hemoglobin concentrations, using NIRS, local cerebral
blood ﬂow (CBF), using DCS, and blood ﬂow velocity (CBFV) in the
middle cerebral artery, using TCD. Robust and persistent increases in oxy-
hemoglobin concentration, CBF and CBFV were observed. A signiﬁcant
agreement was found between macro-vascular (TCD) and micro-vascular
(DCS) hemodynamics, between the NIRS and TCD data, and also within
NIRS and DCS results. The relative cerebral metabolic rate of oxygen,
rCMRO2, was also determined, and no signiﬁcant change was observed.
Our results showed that the combined diffuse optics-ultrasound technique is
viable to follow (CVR) and rCMRO2 changes in adults, continuously, at the
bed-side and in real time.
© 2010 Optical Society of America
OCIS codes: (170.3660) Light propagation in tissues; (170.3890) Medical optics instrumen-
tation; (170.6480) Spectroscopy, speckle; (170.7170) Ultrasound; (290.4210) Multiple scatte-
ring.
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The inherent ability of the cerebral vasculature to conserve constant cerebral blood ﬂow (CBF)
over a wide range of cerebral perfusion pressure (CPP) is known as the cerebral autoregulation
(CAR) [1,2]. One of the main mechanisms responsible for CAR is the ability of the cerebral
arterioles to vasodilate/vasoconstrict in response to chemical and other stimuli. This is also
known as the cerebral vasomotor reactivity (CVR), and is very important for the maintenance of
healthy brain function through CAR and the general metabolic regulation of the brain tissue [3].
In the clinics and in research settings, CVR is assessed by the use of various stimuli such as
carbon-dioxide(CO2)inhalation[4],breathholding,hyperventilationandacetazolamide(ACZ)
administration [5,6]. The ACZ administration andCO2 inhalation are the most frequently used
of such stimuli. However, sinceCO2 inhalation can cause discomfort due to gasping especially
in non-cooperating patients, ACZ administration is often preferred to assess CVR [7]. An intra-
venous (i.v.) dose of 500 to 1000 mg of ACZ, in humans, dilates the arterioles globally without
producing any (or minimal) change in the blood pressure. The dilation of the arterioles reduces
the resistance against blood ﬂow while CPP is preserved. Therefore, the CBF increases glob-
ally both in the micro-vasculature and the major cerebral arteries (macro-vasculature) [8–11].
At these doses, it is generally assumed that this corresponds to a measure of the maximal CVR
and can be used to infer information about the vascular reserve.
To date, a variety of techniques were used to follow the effect of ACZ administra-
tion on CBF; single-photon-emission-computed-tomography (SPECT) [12,13], ﬂow-sensitive-
alternating-inversion-recovery (FAIR) perfusion MRI [14], Continuous-arterial-spin-labeling
(CASL) MRI [15], H15
2 O Positron-emission-tomography (PET) [16] and transcranial Doppler
(TCD) ultrasonography [17–19]. In general, these techniques are reliable but they are often
expensive (SPECT, FAIR, CASL, PET), are limited to the macro-vasculature (TCD), require
patient transport (SPECT, FAIR, CASL, PET) or injection of contrast agents (SPECT, PET).
They are not, therefore, applicable to all patients. A non-invasive, bed-side technique that al-
lows access to the micro-vascular and local CBF without any contrast agents and with relative
ease of use and deployment is desirable.
Near-infrared spectroscopy (NIRS) or diffuse optical spectroscopy (DOS) is a non-invasive,
portable method for continuous and bedside recording of cerebral, microvascular, blood oxy-
gen saturation (StO2) and the total hemoglobin concentration (THC) [20, 21]. The method
is based on the fact that the near-infrared light (∼650-950 nm) can penetrate several cen-
timeters into deep tissues where it is predominantly absorbed by oxy- and deoxy-hemoglobin
species [20,21]. NIRS provides a direct measure of oxy- and deoxy-hemoglobin concentration
as well as total hemoglobin concentration [THC, often proportional to the cerebral blood vol-
ume (CBV)] [20]. NIRS could also offer high temporal resolution (∼ms) to observe transient
hemodynamic phenomena such those in response to functional stimuli. Due to these properties,
NIRS has emerged as a promising bed-side monitor [21,22].
In order to estimate CBF, NIRS looks at either the changes in CBV or uses exogenous tracers
such as indo-cyanine green (ICG) [21,22]. However, it is possible that CBF is disassociated
from CBV in some pathological conditions. Moreover, the use of exogenous tracers for CBF
assessment [23,24] are prohibitively difﬁcult in the case of transient measurements [25]. For
example, Tachtsidis et. al. [26] and Schytz et. al. [6] have used ICG to measure CBF changes
in response to ACZ administration and have reported that they were unable to obtain reliable
CBF measurements. Therefore, NIRS has typically been used for the transcranial measurement
of the cerebral blood oxygenation and is often accompanied with other modalities like PET,
SPECT or TCD to measure CBF [13,26–28].
In this study, we demonstrate successful measurements of CBF in response to ACZ adminis-
tration by using a related technique, diffuse correlation spectroscopy (DCS) [or diffuse-wave-
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micro-vascular, local CBF in deep tissues without any need of tracers. The technique has been
validated in vivo, in tissues, against different standard methods for CBF measurement [22] such
as Doppler ultrasonography, arterial-spin-labeled MRI, Xenon-CT, laser Doppler and against
invasive and non-invasive measures of physiology. Currently, it is able to measure only the
relative changes in CBF but recent reports suggest that with proper calibration and better phys-
ical modeling it has the potential for absolute measurements [22,31,32]. In adult human brain,
DCS was ﬁrst utilized to measure the hemodynamic response to functional stimuli [33, 34].
Later on, in clinical populations, DCS use was reported in premature born babies [31,32], in
neonates born with congenital heart defects [35], traumatic brain injury patients [36] and in
acute ischemic stroke patients [37].
In most of these studies (including the present study), DCS is combined with NIRS so that
the measures of microvascular CBF and oxy- and deoxy-hemoglobin concentrations could be
employed together to assess the cerebral metabolic rate of oxygen extraction (CMRO2). The
measurement of CMRO2 ,which is proportional to the rate at which oxygen is consumed in
the brain by metabolic processes, is potentially of great importance for the clinical assessment
of the functioning of the cerebral tissue, for the evaluation of the extent of cerebral injury due
to cerebrovascular diseases and for predicting the tissue survival [38,39]. Preliminary studies
have shown that CMRO2 could be a more useful clinical measure than CBF or cerebral tissue
oxygenation alone [40].
Unfortunately, bed-side measurements of CMRO2 are prohibitively difﬁcult. Currently avail-
able modalities for rCMRO2 assessment in clinical settings, PET, SPECT and MRI require pa-
tient transport, lengthy measurement times,costly equipment and use of ionizing radiation (in
the case of PET and SPECT). In addition rCMRO2 data, measured with these modalities are
available only at limited time-points. Therefore, it is not surprising that the rCMRO2 change
upon ACZ administration is still being debated [5,41,42] with contradictory reports [7]. The
diffuse optical methods that we employ are the current prominent promising modalities for
bed-side use to measure the rCMRO2.
The CVR and CMRO2 measurements in response to ACZ administration may have a clinical
signiﬁcance for the management of patients with acute and/or chronic cerebrovascular diseases.
For example, the CVR for patients with severe steno-occlusion of the carotid artery were inten-
sively studied while there is a higher stroke risk for patients with steno-occlusive diseases who
also suffer impaired CVR [43, 44]. Therefore, bed-side, continuous and real-time rCMRO2
measure with the hybrid NIRS-DCS technique may help the clinicians to guide therapeutic
strategies.
In the present work, we have applied a hybrid NIRS-DCS device to follow CBF, THC and
CMRO2 changes after ACZ bolus continuously on ten healthy subjects. Furthermore, we have
utilized a clinical TCD instrument to measure the macro-vascular cerebral blood ﬂow velocity
(CBFV) in the middle-cerebral artery (MCA). This enabled us to measure the CVR for micro-
and macro-vasculature simultaneously along with NIRS measures of micro-vascular oxy- and
deoxy-hemoglobin concentrations. By acquiring data from two hemispheres, we were able to
assess the hypothesis that the changes are similar and global in healthy subjects. To the best of
our knowldge, this study is the ﬁrst report of the comparison of DCS to TCD in adults for CVR
assessment.
2. Materials and methods
2.1. Measurement protocol
The measurements were carried out at the Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain where the study protocol was approved by the local ethics review board. Before the
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measurement each subject underwent a general clinical assessment and a detailed survey was
ﬁlled to verify that they were qualiﬁed as “healthy” subjects with no prior cerebrovascular
problems. The subjects were placed in a supine position in a quiet room and venous catheter
was inserted into the right antecubital vein for the drug injection.
Optodes (optical probes) ﬁxed on black foam pads were placed symmetrically on the fore-
head, ∼1cm left and right of the mid-line, to avoid the sinuses [Fig. 1(b)]. The optodes were
tightly attached onto the skin using medical tape and further by the head-frame used for placing
the transcranial Doppler ultrasound probes.
Both left and right middle cerebral arteries MCA were insonated through the temporal acous-
tic window by an experienced neurologist. After placing the optodes and TCD probes and after
optimizing the optical and ultrasound signals, ﬁve minutes of baseline data were obtained. ACZ
(see below for details) was then injected for ∼1 minute and the hemodynamics was followed
concurrently throughout with both optical and ultrasound methods for another 20 min after
ACZ infusion. All events were marked synchronously for both optics and ultrasound [Fig. 1(a)].
Heart rate and systolic, diastolic and mean blood pressures were measured before ACZ injec-
tion and at the last 2 minutes of the measurement with an auto-inﬂated blood pressure monitor
(OMRON M6, HEM-7001-E).
2.2. Acetazolamide
Acetazolamide is a selective inhibitor of carbonic anhydrase (EC 4.2.1.1). Intravenous (i.v.)
administration of a dose >10mg/kg causes the inhibition of carbonic anhydrase activity in most
tissues and increases the CBF by the dilation of the arterioles [41,45]. In this work, 1000mg
Acetazolamide(ACZ) dissolved in 10ml of saline was given as a bolus through an i.v. catheter.
2.3. Optical method
We have utilized two instruments (NIRS and DCS) that were mounted together on a portable
cart and were synchronized through custom software and hardware in a similar manner to
previous studies [33,46]. The NIRS measurements were carried out in the frequency-domain
(110MHz) with 690nm, 785nm and 830nm lasers and two PMTs for light detection (ISS model
95230Imagent)[47].Asdepictedin[Fig.1(b)],asinglesource-detectorseparation(2.5cm)was
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(one for each hemisphere).
The successful use of a single-source detector separation frequency domain NIRS with DCS
was reported in many of the pioneering studies [22,33] but often with corrections for partial
volume effects in adults [33]. Since we used a modiﬁed form of the Beer-Lambert law, the main
concern here was to be able to accurately evaluate the effective optical pathlength [differential
pathlength factor (DPF)] [48,49]. This required us to consider partial volume effects due to the
presence of superﬁcial layers such as the skull and scalp tissues. To this end, we have used a
correction factor, i.e. a partial pathlength factor (PPF) based on the previous studies [33,50]. In
particular, we have utilized the DPF values that were measured with a time-resolved NIRS in
Ref. [51] ( DPF=5.86 at 832nm and DPF=6.51 at 690nm averaged over 50 male and 50 female
with median age of 33) ,and the PPF values for the same ACZ challenge, reported in Ref. [52]
(PPF=0.44 for 2.5cm source-detector separation). We note that these corrections do not, in
general, alter the trends but they affect the absolute values. The absolute values of the changes
are also important when assessing the CMRO2 changes since DCS may have a different partial
volume effect (see below). We employed the THC results to derive an alternative CVR index
according to the relation CVRTHC = DTHC
THCbl ×100. Throughout this paper, the subscript bl is to
indicate the baseline values and D shows the changes from the baseline.
The CBF was assessed with DCS. Like NIRS, DCS also uses the biological window to
penetrate in deep tissue but DCS uses intensity correlation of the scattered light to evalu-
ate the motion of the scatterers, i.e. in this case red blood cells [22]. This intensity corre-
lation data are then ﬁtted using the solutions for the photon correlation diffusion equation
in a semi-inﬁnite geometry to extract the information about movement of the light scatter-
ers in deep tissue (blood ﬂow) [22]. The DCS measures are used to determine relative cere-
bral blood ﬂow (rCBF =
DCBF+CBFbl
CBFbl ) and further to derive a “standard” CVR according to
CVRDCS = (rCBF −1)×100.
DCS device uses two long-coherence-length CW lasers at 785nm and eight avalanche-
photodiode (APD) detectors whose output is fed to a custom-built hardware autocorrelator. In
this measurement the same source-detector separation as NIRS was used for the DCS measure-
ments in a “cross formation” [Fig. 1(b)] enabling the measurement of CBF at roughly the same
tissue volume as the NIRS data. The equipment, the analysis method and the probe were de-
scribed in details in our previous studies [22,33,37].
The optical data acquisition is interlaced between a 0.5 second of NIRS and 3 seconds of
DCS measurements. Since no light leakage from source of one probe to the detector of the other
is observed, NIRS and DCS measurements were carried out in both probes simultaneously to
reduce the measurement time per data point leading to a measurement time of about 4 seconds.
The changes in rCMRO2 are calculated for each hemisphere separately using [53]:
rCMRO2 =
￿
DCMRO2+CMRO2,bl
CMRO2,bl
￿
=
￿
1+gr
DHb
Hbbl
￿
×
￿
1+gt
DTHC
THCbl
￿−1
×(rCBF) (1)
where gr =
DHbV·Hbbl
DHb·Hbbl,V and gt =
DTHCV·THCbl
DTHC·THCbl,V with HbV and THCV being the baseline deoxy-
hemoglobin and total hemoglobin concentrations in the venous compartment respectively and
Hb and THC representing the same in tissue. Finally rCBF represents relative cerebral blood
ﬂow as deﬁned above.
The rCMRO2 analysis is carried out by assuming gt = gr = 1 and baseline THC of
100mM and oxygen saturation level (StO2 =
[HbO2]bl
THCbl = 71%, [HbO2]bl being the baseline
oxy-hemoglobin concentration [54]). This implies 71 mM for oxy-hemoglobin and 29 mM for
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2.4. Transcranial Doppler ultrasound
CBFV recording of the MCA was obtained with a transcranial Doppler (TCD) instrument
(DWL MultiDop-T digital, DWL Elektronische Systeme GmbH). Two probes are used in a
range-gated and pulsed-wave mode at a frequency of 2 MHz. The probes were positioned over
the temporal bone bilaterally using a standard head frame (Diamon®, DWL) that permitted a
constant insonation angle. Simultaneous and continuous measurement of both MCA was per-
formed at a depth of 50 to 60 mm (Fig. 1).
The TCD data were employed to calculate the relative cerebral blood ﬂow velocity
(rCBFV =
DCBFV+CBFVbl
CBFVbl ) and later to calculate CVR values. The CVR values are calculated
from TCD measures according toCVRTCD = (rCBFV −1)×100. Moreover, we have replaced
the rCBFV measures with the rCBF data in Eq. (1) in order to re-calculate the rCMRO2 values
based on NIRS and TCD measurements.
2.5. Statistical analysis
NIRS, DCS and TCD data are stored as continuous variables over time. The data for the last
2 minutes of the measurement are then averaged to obtain the relative change from averaged
5 minute baseline (i.e. before injection) data. All values are reported as mean ± standard-
deviation (STD) and are used for further calculations. The two sided Wilcoxon rank sum test
with 95% conﬁdence level is used to compare the data from left and right hemispheres as well
as the DCS and TCD data with the null hypothesis that the distribution of two samples does
not differ. The Wilcoxon-Mann-Whitney test (U-test) is used to evaluate the effect of the drug
(ACZ) on the NIRS, DCS and TCD parameters (R project [55]). Pearson-product-moment-
correlation-test is used to test for the correlation within and in-between optical and ultrasound
modalities [55].
3. Results
We have recruited ten healthy volunteers (8 males and 2 females), age 30.6 ± 8 years(mean ±
STD). Systolic and diastolic mean-arterial-blood-pressures together with heart rate are meas-
ured at the beginning (during 5 minutes baseline measurement) and at the last 2 minutes of
the measurement with the blood pressure monitor. No change is observed upon ACZ admin-
istration among the studied subjects, in accordance with [11]. All ten subjects completed the
study without any adverse affects. However, TCD data on one subject was missing because of
technical issues.
Figures 2(a), 2(b), and 2(c) show the temporal evolution of the micro- and macro-vascular
hemodynamics, averaged for all studied subjects. Figures 3(a), 3(b), and 3(c) show box-plots
of the population data separately for right and left hemispheres and the overall results is sum-
marized in Table 1. We now outline the results from different parameters in details.
Figure 2(a) shows the temporal evolution of the NIRS results averaged over the whole pop-
ulation. After ACZ administration, as expected, the oxy-hemoglobin concentration increased
and deoxy-hemoglobin concentration decreased slightly. The resulting population data is fur-
ther summarized in Fig. 3(a). For the whole population, the NIRS results for right and left
hemispheres did not differ signiﬁcantly (p=0.24 for oxy-hemoglobin and p=0.1 for deoxy-
hemoglobin). Therefore, the right and left hemisphere data were averaged for the rest of the
calculations which indicate that the oxy-hemoglobin increased by 10.1±6.6mM and the deoxy-
hemoglobin decreased by 1±1.6mM, after the ACZ administration compared to the baseline.
However, while we have observed a signiﬁcant increase in the oxy-hemoglobin concentration
after ACZ administration (p=0.0039), the decrease of deoxy-hemoglobin was not statistically
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deoxy-hemoglobin measurement ( STD
mean(%) = 153). If we further use the assumed baseline
values (see Section 2.3) then we obtain a 14.3% increase for oxy-hemoglobin and 3.6% de-
crease for deoxy-hemoglobin concentration changes.
rCBFV and DCS rCBF changes due to ACZ infusion are shown in Fig. 2(b) for all subjects.
As seen in Fig. 2(b), as expected, both rCBF and rCBFV values increase after ACZ administra-
tion. The rCBF and rCBFV values for the whole population from the right and left hemispheres
is summarized in Fig. 3(b). Similar to NIRS data, since the right and left hemisphere data for
DCS (p=0.97) and for TCD (p=1.0) do not differ signiﬁcantly, the right and left data for DCS
and for TCD are averaged for subsequent calculations. rCBF measured by DCS and rCBFV
measured by TCD data are in good agreement (p=0.27). We note that since the changes in CBF
and CBFV were relatively tight across the whole population, i.e. the spread across subjects was
to the same order as individual standard-deviations, we did not observe a correlation (r=-0.05,
p=0.9) between two modalities but, as reported above, we have observed a good agreement.
The NIRS data was also compared to TCD results. We did not ﬁnd a signiﬁcant correlation
of rCBFV measures with either oxy-hemoglobin (r=0.307, p=0.422) or with deoxy-hemoglobin
concentration changes (r=0.109, p=0.78).
We have also compared the two optical modalities. We have found a strong correlation
between rCBF measures with both oxy-hemoglobin concentration data (r=0.716, p=0.0198)
and deoxy-hemoglobin concentration changes (r=-0.9, P=0.0004). The negative correlation be-
tween deoxy-hemoglobin and rCBF is because rCBF and deoxy-hemoglobin concentration
changes after ACZ are in opposite directions. Overall, this is expected since in this particu-
lar challenge where the hemodynamics are driven by a series of biochemical events that lead
to the dilation of the arterioles with minimal (see below) alterations in oxygen metabolism,
increased CBF leads to increased blood oxygenation in a proportional manner.
CVR indices were calculated from rCBF, rCBFV and NIRS data as described in Sec-
tions 2.3 and 2.4. They show 29±17.5% (Mean± STD) increase according to DCS measures,
36.9±10.8% increase according to TCD and 9.1±5.6% increase according to NIRS after ACZ
administration.
Furthermore, we have also calculated the so-called “Grubb exponent” [56] which is the ratio
of THC changes to CBF changes using a logarithmic formulation [57]. The Grubb exponent
was ﬁtted to be 0.23 for our test which is in reasonable agreement with the literature.
The rCMRO2 changes were calculated point-by-point from NIRS and DCS data as described
in Section 2.3. The average rCMRO2 change with time over all studied subjects is depicted in
Fig. 2(c). Interestingly, rCMRO2 shows an initial increase which partly recovers to the base-
line towards the end of the study which corresponds to the period that is averaged for all the
measurements. Note, however, that the changes are small compared to the rCBF and rCBFV
values. Similar to NIRS and DCS data, rCMRO2 values for right and left hemispheres are also
statistically identical (p=0.064). Figure 3(c) shows the box-plot of rCMRO2 changes for the
whole population compared to the baseline after ACZ administration. For the overall popula-
tion, the change observed for rCMRO2 (9.9±15%) after ACZ administration is not signiﬁcant
(p=0.131), i.e. CMRO2 calculated from NIRS and DCS data is unchanged after ACZ adminis-
tration.
In order to compare local micro-vascular CBF and macro-vascular CBFV, rCMRO2 was
also calculated point-by-point using NIRS and TCD data as described in Section 2.4 (data are
not shown). As for rCMRO2 values calculated from NIRS and DCS measures, the right and
left hemispheres are statistically same in the case of rCMRO2 data obtained from NIRS and
TCD measurements (p=0.258). However, the rCMRO2 values from NIRS and TCD data show
a signiﬁcant change upon ACZ infusion (p=0.0039) with 23.1±13.1% (mean ± STD) , i.e.
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(a) the oxy- and deoxy-hemoglobin changes due to ACZ administration (NIRS data);(b)
hemodynamic response to ACZ observed by changes in CBF measured by DCS and CBFV
measured by TCD; and (c) changes in rCMRO2 calculated point-by-point from changes in
oxy- and deoxy-hemoglobin and rCBF. Vertical bold lines show the start of the baseline,
start of injection, end of injection, and end of the measurement respectively. The data be-
tween the vertical dashed line and the end of the measurement have been averaged and used
for further analysis. The error bars show the standard-deviation values at about 1.5 minute
intervals.
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and TCD data shows a signiﬁcant increase upon ACZ infusion.
Table 1. Mean (± standard-deviation, STD) and p-values for optical and ultrasound data.
Superscript, ∗, implies that observed change is statistically signiﬁcant (p<0.05)
Case Mean STD p-value
DHbO2 (mM)∗ 10.1 6.6 0.0039
DHb (mM) -1 1.6 0.131
D rCBF∗
DCS (%) 29 17.5 0.0019
D rCBFV∗
TCD (%) 36.9 10.8 0.0078
DrCMRO2 (%) 9.9 15 0.131
4. Discussion
WehavestudiedtheeffectsofACZadministrationoncerebralhemodynamicsfrombothmacro-
vascular (using TCD) and micro-vascular (using diffuse optics) perspectives. Furthermore, by
combining two diffuse optical techniques, NIRS and DCS, we were able to deduce informa-
tion about changes in CMRO2. We now discuss our ﬁndings, compare them to the literature,
highlight its strengths and weaknesses, and ﬁnally suggest some further clinical applications.
ACZ caused (see Section 3) robust, persistent increases in oxy-hemoglobin concentration,
CBF and CBFV in accordance with other reports on ACZ effect [6,7,41,52]. These changes
are known to be due to the dilation of the micro-vasculature in response to ACZ stimulus. In
addition, since ACZ is injected in the blood stream, the changes observed in the brain in healthy
people are global [7,52]. This justiﬁed our use of the forehead, which is easily accessible, for
measuring the micro-vascular hemodynamics in the frontal lobes as a measure CVR for a given
hemisphere. We have conﬁrmed this by observing statistically same changes for the left and
right hemispheres [Figs. 3(a) and 3(b)].
According to our results oxy-hemoglobin concentration increased by 14.3% of its baseline
value. The deoxy-hemoglobin decreased by 3.6% of its baseline value on average, leading to
a 10.7% THC increase after ACZ administration. However the measured changes for deoxy-
hemoglobin concentration were not statistically signiﬁcant (p=0.13, Wilcoxon-Mann-Whitney
test). This was most probably due to a higher, relative standard deviation of deoxy-hemoglobin
concentration changes. Never the less, our values for mean THC changes after ACZ injection
are in good agreement with the data reported elsewhere with continuous-wave-NIRS (THC in-
creased by 5.7%) [13], time-resolved-NIRS (THC increased by 10.6%) [52] and 99mTC SPECT
(THC increased by 9.4%) [12].
Since a single source-detector separation was used for the NIRS measurements, we have only
measured the changes of oxy- and deoxy-hemoglobin concentrations, compared to their values
before ACZ administration and not the absolute values. Furthermore, as detailed in Section 2.3,
we have utilized literature values for the assumed optical pathlengths (DPF) with corrections
for the partial volume effects (PPF). This may have led to some errors in our data due to inverse
dependence of the reported oxy- and deoxy- hemoglobin concentrations on the assumed DPF
and PPF values [48,49]. However we note, that the subjects were in good health, and that we
have considered their mean age, gender and the laser wavelength when using the DPF values
from the literature [51]. Furthermore, the PPF values in the literature [52] were actually meas-
ured using the same ACZ challenge. The standard-deviation of the values from these reports
gives us an idea of the errors that could be introduced to our results and since they are within
the standard-deviation of our NIRS data, we expect that our errors are minimal. A future study
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The main impact of this work is to introduce the DCS technique to measure local changes of
CBF in the micro-vasculature to follow the ACZ effect on CBF. DCS continuously measures
local rCBF directly, without any further need to utilize isotope or non-isotope tracers. Our
study shows 29% increase in the rCBF after ACZ bolus in healthy subjects, which is in good
agreement with several studies ( 32.5% increase of rCBF on average) [14,58,59]. The reported
values for the CBF change due to ACZ, range from 25% using 133Xe SPECT [60] to 70% using
133Xe [5] inhalation techniques. These results partly depend on the measurement technique.
They also depend on the age and gender of the studied population.
TCD is the primary modality used for CVR assessment, which is mainly due to its acces-
sibility and simplicity compared to the other relevant techniques. Both our work and the oth-
ers [18,58,59,61,62] suggest that an intravenous administration of ACZ induces a signiﬁcant
increase in rCBFV. We have found a 37% increase of rCBFV in MCA after ACZ bolus, which
is in good agreement with the results reported in the above cited studies.
The CVR values were also calculated from THC data and led to 9.1±5.6% increase after
ACZ injection. It is three and four times smaller than the CVR values calculated from DCS and
TCD data, respectively. This deviation is expected since the NIRS measured THC changes do
not directly correspond to the blood ﬂow changes [25]. However, if we use the Grubb’s formu-
lation [56], with the Grubb exponent that we have measured (G=0.23 for DCS/NIRS [57]), we
can correct for this under-estimation. We note that the calculation of the exponent depends on
the assumed baseline value for THC.
Furthermore, we have, to the best of our knowledge, reported the ﬁrst comparison of DCS
measures of local microvascular CBF to TCD measures of middle-cerebral artery CBFV in
adults. A comparison between micro- and macro- vasculature response with a similar approach
(TCD-DCS) was previously reported in premature neonates by us [63] and others [64]. In both
studies, the authors looked at the absolute, baseline values of CBFV and CBF in premature
born infants and reported signiﬁcant correlations between TCD and DCS results. In an earlier
paper [63], it was attempted to compare changes due to head-of-bed challenge in the premature
born infants. There a non-signiﬁcant change was induced, which was observed by both TCD
and DCS. Since the partial volume effects are often negligible in premature born infants with
their thin skulls and scalps, it was not obvious whether a correlation would be observed in the
adult brain. Furthermore, we also note that, in the same work, R-Labarbe et. al. [64] demon-
strated that the use of DCS and NIRS simultaneously has provided better estimates of CMRO2
than NIRS only measures.
One immediate consequence of having concurrent measures of blood ﬂow in micro- and
macro-vasculature is the capability of comparing their interaction mechanism. This question
was indirectly addressed during the early works carried out to validate TCD against standard
133Xe inhalation SPECT for CBF measurements [58, 59, 65]. They have found a signiﬁcant
correlation between CBFV values (measured with TCD) and CBF values in the same artery
(measuredwithSPECT)[59]orCBFVvaluesinthearterywithlocalCBFvaluesintheterritory
of that same artery (measured with SPECT) [58,65]. However the prediction of the local CBF
on the basis of CBFV data is only valid if among other factors the diameter of the large vessels
remain unchanged [66]. A > 4% increase in the diameter of the MCA upon ACZ administration
was reported [18], which may hinder this comparison. Nevertheless, our results showed that
the local blood ﬂow change in micro-vasculature, rCBF, and the blood ﬂow velocity change
in the macro-vasculature, rCBFV, are in good agreement for healthy subjects (p=0.27). The
advantages posed by DCS that we have discussed earlier would enable large scale studies on
the interactions between micro- and macro-vasculature.
Our results demonstrate the capability of the hybrid NIRS-DCS technique, to give informa-
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hemoglobin concentration changes in response to ACZ challenge. According to Figs. 2(a) and
2(b), upon ACZ administration oxy- hemoglobin concentration and rCBF increases along with
decrease in the deoxy-hemoglobin concentration. Moreover, the optical data change continu-
ously until the end of measurement. However it should be mentioned that, these ﬁgures show
the average trend over all studied subjects and the dynamics of the changes varies amongst
the individual subjects. In order to interpret the dynamics of the observed changes correctly,
we would have to consider variations in the subject physiology including the weight, age and
gender with continuous measures of the systemic physiology such as the blood pressures and
the arterial pressure of carbon-dioxide in a larger population which is beyond the aim of this
manuscript.
One important factor that could affect the optical measurements, NIRS and DCS, is the
change in superﬁcial tissue oxygenation and blood ﬂow after ACZ bolus especially with a
single source-detector separation which does not allow us to correct for those effects. These
changes, if they occur, would be added to the changes of cerebral tissue oxygenation and blood
ﬂow leading to the misinterpretation of the results from the cerebral tissue. The changes in
superﬁcial tissue oxygenation and blood ﬂow due to ACZ bolus was studied by Tachtsidis et.
al. [26], by CW-NIRS with different source-detector separations, and by Kohri et. al. [52] by
time-resolved-NIRS. They did not observe any changes after ACZ bolus on superﬁcial tis-
sue oxygenation. Furthermore, by utilizing a laser Doppler probe, Tachtsidis et. al. [26] have
conﬁrmed that the blood ﬂow does not also change in the superﬁcial tissues. Based on these
ﬁndings, we have assumed that the superﬁcial tissue oxygenation and blood ﬂow are unchanged
after ACZ injection.
Concurrent measures of oxy-hemoglobin concentration, deoxy- hemoglobin concentration
and rCBF are further used for rCMRO2 calculation. The study of the ACZ effect on rCMRO2
is important for both clinical and methodological reasons. Since ACZ is used as a treatment for
some diseases in addition to its use as a diagnostic tool for CBF studies, the mechanism behind
its CBF effect is of major physiological interest [5]. Moreover some investigators have used the
difference in arterio-venous oxygen content ((a−v)O2) to estimate changes in CBF after ACZ
bolus. This would only be applicable if the rCMRO2 does not change after ACZ administration.
Although today it is mostly agreed that rCMRO2 does not change after ACZ [5,41,62] but there
are some contradictory reports [42].
Based on our NIRS and DCS data, we have calculated rCMRO2 point-by-point over time
[Fig. 2(c)], as described in Section 2.3. Overall, our rCMRO2 data calculated from NIRS
and DCS measures did not show a signiﬁcant change after ACZ administration (p=0.13). We
note that we have a rather high standard-deviation for rCMRO2 data ( STD
mean(%) = 152), which
is mostly due to high relative standard-deviation values in deoxy-hemoglobin concentration
measurement ( STD
mean(%) = 153).
The rCMRO2 values calculated point-by-point from NIRS and TCD data, on the other hand,
have shown a signiﬁcant increase after ACZ infusion (p=0.0039). Since both calculations share
the same NIRS measures, according to Eq. (1) the only difference in the rCMRO2 measures
would be due to the fact that DCS measures micro-vascular blood ﬂow while TCD gives the
blood ﬂow velocity in the macro-vasculature. Hence, due to slightly higher (yet statistically
non-signiﬁcant) values for blood ﬂow velocity from TCD as compared to DCS, an increased
rCMRO2 is obtained. We belive that the rCMRO2 values from NIRS and DCS data is more
reliable and more relevant since they reﬂect local, micro-vascular physiology.
As the NIRS data are used for the rCMRO2 calculation, all the corrections and baseline
approximations that we have used to extract NIRS values affect the rCMRO2 values. We have
also assumed that the deoxy-hemoglobin concentration and THC changes in the venous, and in
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order to test the effects of the assumed baseline values, we have varied the assumed baseline
StO2 and THC values and observed only minor effects on our rCMRO2 measures. For example,
a 10% change in THC caused less than 0.5% change in rCMRO2 value and a 10% change in
StO2 value caused 1.5% change in rCMRO2.
We note that the use of small and relatively simple probes with single source-detector sepa-
ration makes practical for use in critically ill patients specially in the intensive care units. Since
one of our goals is to utilize this data as a “control” group for future studies with carotid artery
diseases and ambulatory stroke patients, this consideration was important. Besides, on those
patients, if they have a unilateral problem, one hemisphere could be used as a control as in our
previous study utilizing a head-of-bed challenge [37].
Moreover, it should be kept in mind that these results are very sensitive to rCBF changes,
which may be the primary main reason for contradictory values reported in the literature for
rCMRO2. This could also immedietly seen based on our rCMRO2 calculations with shared
NIRS but different blood ﬂow data. We did not make any partial volume corrections to our
CBF data obtained by DCS. Partial volume corrections for DCS were proposed in several stud-
iesinthepastforlocalchanges[33,34]andforlayeredtissues[70,71].Whilethiswasexpected,
surprisingly,manyotherstudiesusingstimulithatleadtoglobalchanges,asinourcase,havere-
ported good agreement between DCS and “gold standard” techniques such as Xenon-inhalation
CT without any or minimal partial volume corrections [22,35,37,63,64,72]. Overall, these re-
sults have shown that due to subtle differences between DCS and NIRS, the partial volume
corrections (if any) are not straightforward and further research is needed. However, since the
overwhelming evidence including the excellent agreement we have observed between TCD and
DCS indicate that the corrections can be minimal, we have chosen not to implement them.
The CVR assessment is of great prognostic signiﬁcance for patients with severe stenosis or
occlusion of the large cerebral arteries. This is due to a higher stroke risk for patients with
steno-occlusive diseases who also suffer decreased or exhausted CVR [43,44]. While yearly
incidence of stroke between 2 and 8 % is reported for patients with steno-occlusive carotid
diseases globally [73,74], patients with impaired CVR have higher risk of stroke, between 27
to 55% [44,75]. The CVR test with ACZ may then be of a signiﬁcant value for identifying this
high-risk sub-group of patients. It might also help clinicians to guide therapeutic interventions.
A follow-up study is currently underway to assess the CVR in patients with steno-occlusive
carotid diseases and to study CVR asymmetry in symptomatic and asymptomatic cases. Al-
though similar questions have been addressed before with other modalities, our impact with
diffuse optic-ultrasound techniques is continuous, bed-side measure of CVR both in micro-
and macro-vasculature together with local measures of cerebral tissue oxygenation and oxygen
metabolic rate. In addition it would reduce the complications due to patient transfer and use of
ionizing tracers for CVR measurements.
5. Conclusion
In this study, we have demonstrated that the combined NIRS, DCS and TCD technique could
be applied for the assessment of CVR upon ACZ administration. This is the ﬁrst report where
DCS is compared to TCD in adults. This combination of three portable, continuous and bed-
side measures are advantageous over the other, mainly imaging, modalities used for similar
studies where both the micro- and macro-vascular cerebral hemodynamics are studied. A key
advantage of this approach is that it allows us to measure at the bed-side and without any need
to utilize any tracer. We have demonstrated that macro- and micro-vascular blood ﬂow and
velocity changed in a similar manner and globally. The combination of DCS and NIRS enabled
us to estimate changes in oxy- and deoxy-hemoglobin concentrations hence deriving a measure
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set-up time is relatively short and there are no potential risks such as those due to the use of
ionizing radioactivity, our approach is suitable for clinical settings such as the neuro-intensive
care units.
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